MetaCap

Bio-Techne Corp (TECH)

NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

72.67-0.03 (-0.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TECH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$11.42B
Dividend yield
0.33% ($0.24)
Ex-dividend date
Nov 13, 2026
52-week range
43.20 – 72.88
Day range
72.66 – 72.77
Volume / Avg
3.66M / 2.91M
Beta
—

52-week range

$43.20$72.88

TECH stock today

Shares of Bio-Techne (TECH) finished lower on Nov 20 at $72.67, a drop of 0.04% or $0.03 per share, versus the S&P 500's 3.70% decline. The stock is trading at or near its 52-week high of $72.88, set on Nov 9, 2026, 68.2% above the 52-week low of $43.20. TECH is up 23.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.1%.

At 66.7x trailing earnings, Bio-Techne trades above the peer-group median of 24.7x. Its forward P/E of 31.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Bio-Techne pays an annual dividend of $0.24 per share, a 0.33% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Bio-Techne

Company profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Kim Kelderman
Headquarters
Minneapolis, MN
Employees
3,000

Financial highlights

Full financials

In fiscal 2026, Bio-Techne generated $1.22 billion in revenue, down 0.4% from fiscal 2025, its first annual decline since 2013. Net income was $181.9 million (+147.8% year over year), for a net margin of 15.0% versus a median of 15.1% in the prior 5 years. Gross margin was 65.8% (up from 64.8%) and operating margin 20.7%.

Bio-Techne annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$1.22B$1.22B$1.16B$1.14B$1.11B
Growth-0.38%+5.23%+1.97%+2.81%+18.75%
Net income$181.86M$73.40M$168.10M$285.26M$272.05M
EPS (diluted)$1.16$0.46$1.05$1.76$1.66

Analyst forecast

Forecast

Consensus (13 analysts)

hold

Avg. price target

$70.50-2.99%

  • Strong buy 0
  • Buy 0
  • Hold 12
  • Sell 1
  • Strong sell 0

Target range

Low $50.00High $73.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$0.36 vs $0.40
Surprise
-10.00%

Dividends

Dividend history
Annual dividend
$0.24
Last payment
$0.08
Ex-dividend date
Nov 13, 2026
Pay date
Nov 23, 2026

TECH news

All TECH news

Bio-Techne peers

Health Care sector
TECH peer companies
CompanyPrice% ChgMarket capCompare
RGENRepligen Corporation163.81-3.81%$10.47Bvs TECH
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs TECH
QGENQiagen N.V.49.30-0.66%$10.18Bvs TECH
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs TECH
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs TECH
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs TECH
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs TECH
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs TECH

Indexes, lists and sector

Bio-Techne stock FAQ

What is Bio-Techne's stock price today?

TECH last traded at $72.67 as of Nov 20, 4:00 PM EST, down 0.04% on the day. Prices are delayed at least 15 minutes.

Does Bio-Techne pay a dividend?

Yes. Bio-Techne pays $0.24 per share annually, a 0.33% yield. The most recent dividend of $0.08 had an ex-dividend date of Nov 13, 2026.

What is TECH's P/E ratio?

TECH trades at a trailing P/E ratio of 66.67 and a forward P/E of 31.43, compared with a median of 24.7 for its closest peers.

Is Bio-Techne in the S&P 500?

Yes. Bio-Techne (TECH) is a constituent of the S&P 500 index.

Who is Bio-Techne's CEO?

Mr. Kim Kelderman is the chief executive officer of Bio-Techne Corp, which has about 3,000 employees.

Has TECH ever split its stock?

Yes. The most recent TECH stock split was a 4-for-1 split on Nov 30, 2022, one of 3 splits on record.

What is the TECH 52-week high?

The 52-week high for TECH is $72.88 and the 52-week low is $43.20. The stock is currently 0.3% below its high.

Compare TECH